Hints and tips:
...The pharmaceutical company’s criticism of a competing product comes as the US Food and Drug Administration considers whether to authorise Merck’s antiviral drug molnupiravir, the first easy-to-administer...
...Prosecutors initially focused on high-prescribing doctors and on the pharmaceutical companies that manufactured and marketed the opioids....
...The lawsuit names William Barr, the US attorney-general, and Timothy Shea, the acting administrator of the DEA, as defendants....
...From there he went to work for a law firm before becoming general counsel of Barr Pharmaceuticals, where he gained a reputation as a creative and pugnacious lawyer....
...Mr Bisaro, a lawyer by trade, first entered the world of pharma in 1992 when he joined Barr Pharmaceuticals as chief legal counsel, later becoming chief operating officer....
...The pharmaceuticals group’s decision to sell Lucozade and Ribena will cause pangs of nostalgia across the UK, their main market. It is the right decision, however....
...This compares well to generics deals over the last five years which have mostly been at about 14-15 times ebitda, and the 13.3 times multiple Teva paid in 2008 for its $7.5bn acquisition of US-based Barr...
...Teva already controls 18 per cent of the global market, following its $7.5bn takeover of Barr Pharmaceuticals of the US in 2008....
...The largest-ever tie-up in the generics industry, the acquisition of Barr Pharmaceuticals by Teva for $7.5bn, should close by the end of 2008, while Alpharma finally acquiesced to King Pharmaceuticals’ $1.6bn...
...But we would say patent expiration is important for pharmaceutical companies and look across the industry at the issue....
...In November, Cray’s Jaguar supercomputer, installed at the Oak Ridge National Laboratory, also passed that milestone....
...Lehman had been advising on and financing many deals, including Teva Pharmaceutical’s $8.8bn merger with rival Barr Pharmaceuticals....
...It is this, combined with renewed pricing pressure, that is driving the generics industry itself to consolidate through deals such as Teva’s with Barr....
...A slightly riskier deal involves the combined cash-and-stock acquisition of generic drug company Barr Pharmaceuticals for $66.50 a share by rival Teva....
...An unlikely union given national history perhaps, but just the latest in a series of consolidation among the world’s generic pharmaceuticals....
...Teva Pharmaceutical Industries, the Israeli generic drug maker, agreed to buy rival Barr Pharmaceuticals for $7.46bn....
...The district of New Jersey court on Monday evening ruled invalid the patent on Yasmin, so paving the way for Barr Laboratories, the US-quoted generic drug manufacturer that launched the challenge, to introduce...
...Barr Laboratories and AstraZeneca, 1.6 per cent cheaper at £20.65, could be interested. Shire was also propped up by positive comments from Morgan Stanley....
...Barr Pharmaceuticals rallied 10.2 per cent this week to $54.83 as the company reiterating its earnings outlook on Wednesday....
...Shire Pharmaceuticals has thrashed out an agreement with Barr Laboratories of the US that will delay any generic challenge to the UK group’s best-selling attention deficit hyperactivity disorder drug, until...
...Actavis has completed more than 20 acquisitions including in Europe, the US and India in recent months, but lost out to Barr Pharmaceuticals of the US late last year in a bid for Pliva of Croatia....
...Barr Pharmaceutical dropped 2.9 per cent to $53.53 after the Food and Drug Administration approved the production of a generic version of its oral contraceptive pill by Watson Pharmaceutical....
...It marks the latest chapter in the consolidation of the generic drugs sector, which has witnessed Teva’s $7.4bn takeover of Ivax, and Barr Pharmaceuticals’ purchase of Croatia’s Pliva for $2.5bn....
...In 2001 Eli Lilly was locked in a legal wrangle with Barr Laboratories, a producer of generic products, over the patent for Prozac, Lilly’s most lucrative drug....
International Edition